CD19 antibodies
Synonyms: B4, Leu-12
RECOMBINANT
Clone:
REA675
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Select a conjugate:
Specifications for CD19 antibodies
Overview

REA675 recognizes the human CD19 antigen, a type I transmembrane glycoprotein of 95 kDa that belongs to the immunglobulin superfamily. CD19 is expressed on B cells throughout most stages of B cell differentiation, though its expression is down-regulated during their terminal differentiation to plasma cells. Expression of CD19 is also found in the majority of B cell–derived malignancies. CD19 is further present on follicular dendritic cells. On B cells, CD19 associates with CD21, CD81, and CD225 (Leu-13) forming a signal transduction complex.

Additional information: Clone REA675 displays negligible binding to Fc receptors.

Alternative names

B4, Leu-12

Detailed product information

Technical specifications

Clone
REA675
Isotype
recombinant human IgG1
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
CD19
Distribution of antigen
B cells, dendritic cells
Resources for CD19 antibodies
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for CD19 antibodies
Publications
  1. Fujimoto, M. et al. (2000) CD19 regulates intrinsic B lymphocyte signal transduction and activation through a novel mechanism of processive amplification. Immunol. Res. 22 (2-3): 281-298
  2. Wood, B. L. et al. (2007) 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B Clin. Cytom. 72: 14-22
  3. Poe, J. C. et al. (2001) CD19, CD21, and CD22: multifaceted response regulators of B lymphocyte signal transduction. Int. Rev. Immunol. 20 (6): 739-762
  4. Clinical and Laboratory Standards Institute (CLSI) (2007) Enumeration of immunologically defined cell populations by flow cytometry, CLSI document H42-A2 (ISBN 1-56238-640-9). CLSI Approved Guideline - Second Edition
  5. Nadler, L. M. et al. (1983) B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol 131 (1): 244-250
  6. Clinical and Laboratory Standards Institute (CLSI) (2007) Clinical Flow Cytometric Analysis of Neoplastic Hematolympoid Cells, CLSI document H43-A2 (ISBN 1-56238-635-2). CLSI Approved Guideline - Second Edition
  7. van Dongen, J. J. M. et al. (2012) EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26 (9): 1908-1975
  8. Tedder, T. F. et al. (2002) CD19-CD21 complex regulates an intrinsic Src family kinase amplification loop that links innate immunity with B-lymphocyte intracellular calcium responses. Biochem. Soc. Trans. 30 (4): 807-811
  9. Rothe, G et al. (2012) Consensus protocol for the flow cytometric Immunophenotyping of hematopoietic malignancies. Leukemia 10 (5): 877-895
  10. Stelzer, G. T. et al. (1997) U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry 30 (5): 214-230